PE20010459A1 - Uso de un compuesto calciolitico con un agente antiresorcion - Google Patents

Uso de un compuesto calciolitico con un agente antiresorcion

Info

Publication number
PE20010459A1
PE20010459A1 PE2000000756A PE0007562000A PE20010459A1 PE 20010459 A1 PE20010459 A1 PE 20010459A1 PE 2000000756 A PE2000000756 A PE 2000000756A PE 0007562000 A PE0007562000 A PE 0007562000A PE 20010459 A1 PE20010459 A1 PE 20010459A1
Authority
PE
Peru
Prior art keywords
phenoxy
propyl
hydroxy
dimethyl
amine
Prior art date
Application number
PE2000000756A
Other languages
English (en)
Inventor
Maxine Gowen
Larry J Suva
Edward F Nemeth
John Fox
George B Stroup
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of PE20010459A1 publication Critical patent/PE20010459A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE AL USO DE COMPUESTOS INHIBIDORES DE LA ACTIVIDAD DE LOS RECEPTORES DE CALCIO TAL COMO HIDROCLORURO DE N-[(2R-HIDROXI-3-[(3-CLORO-2-CIANO)FENOXI-PROPIL]-1,1-DIMETIL-2-(2-NAFTIL)-ETIL-AMINA, HIDROCLORURO DE N-[(2R-HIDROXI-3-[(3-CLORO-2-CIANO)FENOXI-PROPIL]-1,1-DIMETIL-2-(4-METOXIFENIL)ETIL-AMINA, HIDROCLORURO DE N-[(2R-HIDROXI-3-[(2,3-DICLORO)FENOXI-PROPIL]-1,1-DIMETIL-2-(4-METOXIFENIL)ETIL-AMINA, ENTRE OTROS; CON UN AGENTE DE ANTI-RESORCION TAL COMO ESTROGENOS, 1,25(OH)2-VITAMINA D3, CALCITONINA, MODULADORES SELECTIVOS DE LOS RECEPTORES DE ESTROGENOS, ANTAGONISTAS DEL RECEPTOR DE VITRONECTINA, INHIBIDORES DE LA V-H+-ADENOSINA-FOSFATASA, ANTAGONISTAS src DE SH2, BISFOSFONATOS Y LOS INHIBIDORES DE LA CATEPSINA K. EL AGENTE CALCIOLITICO PRODUCE UN AUMENTO EN LOS NIVELES DE LA HORMONA PARATIROIDEA EN SUERO DE TRES VECES O MAS. LA ADMINISTRACION CONJUNTA DE UN AGENTE CALCIOLITICO CON UN AGENTRE ANTI-RESORCION PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO OSEO MINERAL TAL COMO ENFERMEDAD PERIODONTAL, CONSOLIDACION DE FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDE, OSTEOPOROSIS, HIPERCALCEMIA HUMORAL MALIGNA, ENFERMEDAD METASTASICA DE LOS HUESOS, PROTESIS ARTICULARES
PE2000000756A 1999-07-31 2000-07-31 Uso de un compuesto calciolitico con un agente antiresorcion PE20010459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
PE20010459A1 true PE20010459A1 (es) 2001-06-11

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000756A PE20010459A1 (es) 1999-07-31 2000-07-31 Uso de un compuesto calciolitico con un agente antiresorcion

Country Status (21)

Country Link
EP (1) EP1200076A4 (es)
JP (1) JP2003505502A (es)
KR (1) KR20020016928A (es)
CN (1) CN1367687A (es)
AU (1) AU764716B2 (es)
BR (1) BR0012921A (es)
CA (1) CA2380081A1 (es)
CO (1) CO5180628A1 (es)
CZ (1) CZ2002360A3 (es)
EC (1) ECSP003590A (es)
HK (1) HK1046238A1 (es)
HU (1) HUP0202167A3 (es)
IL (1) IL147875A0 (es)
MX (1) MXPA02001204A (es)
NO (1) NO20020466L (es)
PE (1) PE20010459A1 (es)
PL (1) PL353318A1 (es)
TR (1) TR200200278T2 (es)
UY (1) UY26265A1 (es)
WO (1) WO2001008673A1 (es)
ZA (1) ZA200200784B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
AR018177A1 (es) * 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Also Published As

Publication number Publication date
AU764716B2 (en) 2003-08-28
ECSP003590A (es) 2002-02-25
PL353318A1 (en) 2003-11-17
NO20020466L (no) 2002-03-20
CO5180628A1 (es) 2002-07-30
CA2380081A1 (en) 2001-02-08
JP2003505502A (ja) 2003-02-12
BR0012921A (pt) 2002-06-18
WO2001008673A1 (en) 2001-02-08
CZ2002360A3 (cs) 2002-10-16
MXPA02001204A (es) 2004-05-21
IL147875A0 (en) 2002-08-14
EP1200076A4 (en) 2005-02-09
ZA200200784B (en) 2003-01-29
KR20020016928A (ko) 2002-03-06
CN1367687A (zh) 2002-09-04
HK1046238A1 (zh) 2003-01-03
TR200200278T2 (tr) 2002-06-21
NO20020466D0 (no) 2002-01-29
UY26265A1 (es) 2001-03-16
HUP0202167A3 (en) 2006-07-28
AU6504100A (en) 2001-02-19
EP1200076A1 (en) 2002-05-02
HUP0202167A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
PE20010459A1 (es) Uso de un compuesto calciolitico con un agente antiresorcion
BR112012002143B8 (pt) composto para redução dos níveis de hormônio da paratireóide, composição contendo o referido composto e uso do mesmo
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
PA8452701A1 (es) Agonistas de prostaglandinas
ES2116642T3 (es) Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
CN105193523A (zh) 一种踝关节假体
YU75800A (sh) Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon
PE20001563A1 (es) Antagonistas del receptor de vitronectina
Shevtsov et al. Morphological characteristics of angiogenesis in the myofascial tissues of a limb elongated by the Ilizarov method.
Cook et al. Enhanced bone ingrowth and fixation strength with hydroxyapatite-coated porous implants.
Breusch et al. Effects of the cementing technique on cementing results concerning the coxal end of the femur
Elsasser et al. Deficit of trabecular and cortical bone in elderly women with fracture of the femoral neck.
Farhood et al. A modified approach to the ilium to obtain graft material.
Magnan et al. Sodium fluoride sustained-release bone cement: an experimental study in vitro and in vivo.
Aho et al. Morphology of osteogenesis in bioactive glass interface.
Langlais et al. Weight-bearing early after osteosynthesis of the femoral neck by nail-plate (100 cases)
Reginster Treatment of osteoporosis: where are we and where are we going to.
Orcel et al. Spontaneous fissures and fractures of the legs in patients with osteoporosis treated with sodium fluoride
Kim et al. Prevention of New Vertebral Fractures after Treatment with Risedronate, Alendronate or Calcium Carbonate in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation
Duriez et al. Effect of a calcium inhibitor, verapamil, on the development of heterotopic ossifications. An experimental study in rats
Kurock et al. Managing pathologic femoral fractures in malignant bone tumors and skeletal metastases
Brinker et al. Adjunct fibula strut bone graft in resurfacing hip arthroplasty.
Ferrante et al. Correction of nose deviations using latero-septal grafts from irradiated bovine cartilage

Legal Events

Date Code Title Description
FC Refusal